Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Sales (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Return on Sales for 14 consecutive years, with 0.87% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 46.0% year-over-year to 0.87%, compared with a TTM value of 0.92% through Dec 2025, down 29.0%, and an annual FY2025 reading of 0.03%, down 3.0% over the prior year.
  • Return on Sales was 0.87% for Q4 2025 at Karyopharm Therapeutics, down from 0.58% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.56% in Q2 2024 and bottomed at 2.47% in Q1 2021.
  • Average Return on Sales over 5 years is 1.04%, with a median of 0.98% recorded in 2022.
  • The sharpest move saw Return on Sales surged 160bps in 2022, then plummeted -148bps in 2025.
  • Year by year, Return on Sales stood at 0.31% in 2021, then crashed by -474bps to 1.15% in 2022, then fell by -9bps to 1.25% in 2023, then dropped by -7bps to 1.34% in 2024, then soared by 35bps to 0.87% in 2025.
  • Business Quant data shows Return on Sales for KPTI at 0.87% in Q4 2025, 0.58% in Q3 2025, and 0.92% in Q2 2025.